Shares of Iovance Biotherapeutics Inc. (IOVA) have gained more than 60% over the last 4 trading days, thanks to favorable regulatory developments concerning its one-time tumor-infiltrating lymphocyte therapy, Lifileucel.
Lifileucel was granted accelerated approval by the FDA for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor on Feb.16, 2024.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.